Johns Hopkins Researchers Develop Novel Intranasal DNA Vaccine to Combat Drug-Tolerant Tuberculosis Persisters

Tuberculosis remains a formidable global health crisis, persisting as one of the deadliest infectious diseases in human history despite six millennia of coexistence with our species. A team of researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health has unveiled a potentially transformative breakthrough: an experimental therapeutic DNA vaccine administered intranasally. This innovative approach targets the elusive "persister" bacteria that survive conventional antibiotic regimens, a primary driver of treatment failure and disease relapse. The findings, recently published in the Journal of Clinical Investigation, mark a significant pivot in the strategy to manage a disease that continues to claim over a million lives annually.

The Persistent Threat of Tuberculosis

The scale of the tuberculosis (TB) challenge is staggering. Data from the World Health Organization (WHO) indicate that approximately one-quarter of the global population, roughly 2 billion individuals, are carriers of latent TB. While these individuals do not exhibit symptoms, they serve as a massive reservoir for potential future outbreaks. In 2024 alone, more than 10 million people developed active tuberculosis, resulting in 1.2 million deaths.

The core of the problem lies in the bacteria’s sophisticated survival mechanisms. During treatment, antibiotics effectively eliminate the rapidly dividing, metabolically active bacteria. However, a subpopulation of "persisters"—dormant or slow-growing bacteria—often survives these drugs. These microbes can remain sequestered in the lungs, shielded from the immune system and pharmacological agents. When the patient ceases treatment, these survivors can reactivate, leading to a resurgence of the disease. Furthermore, the emergence of multidrug-resistant (MDR-TB) strains has complicated clinical management, often necessitating treatment protocols that span many months or even years, with significant side effects and low patient compliance rates.

Scientific Mechanism: A Dual-Gene Approach

The Johns Hopkins team, led by Styliani Karanika, M.D., an assistant professor of medicine at the Johns Hopkins University School of Medicine, designed the vaccine to bridge the gap between drug therapy and host immunity. The experimental vaccine utilizes two specific genes, relMtb and Mip3α, to prime the body to recognize and eliminate hidden bacterial populations.

The relMtb gene is derived from the TB bacterium itself. It produces the RelMtb protein, which is essential for the pathogen to enter a state of dormancy under stress—such as nutrient deprivation or exposure to antibiotics. By utilizing this specific target, the vaccine teaches the immune system to recognize the very mechanism the bacteria use to "hide" from drugs.

The second component, the Mip3α gene, acts as an immunological recruiter. It produces a signal that attracts immature dendritic cells to the site of administration. Dendritic cells are the "sentinels" of the immune system; they ingest bacterial proteins and present them to T cells. Once primed, these T cells coordinate a targeted, localized strike against the TB bacteria.

By delivering the vaccine through the nose, the researchers aim to induce a robust immune response directly in the respiratory mucosa, the primary portal of entry and site of infection for Mycobacterium tuberculosis. This approach is intended to create long-lasting, site-specific immunity, complementing systemic immune responses.

Chronology of Preclinical Validation

The path to this discovery has been marked by rigorous multi-stage testing. Initial efficacy studies were conducted in mouse models, where the vaccine was administered in tandem with standard first-line TB drug therapy. The results were compelling: the vaccine-treated cohort demonstrated a significantly faster clearance of bacterial loads in the lungs compared to those receiving antibiotics alone. Furthermore, the vaccine effectively reduced lung inflammation and, crucially, prevented disease relapse once the antibiotic course was discontinued.

Expanding upon these findings, the research team demonstrated that the vaccine enhances the efficacy of modern, high-potency antibiotic combinations, including bedaquiline, pretomanid, and linezolid. This synergy suggests that the vaccine could be an effective adjuvant for treating drug-resistant TB, potentially turning the tide against the most difficult-to-treat clinical cases.

Most recently, the researchers evaluated the vaccine in rhesus macaques to assess safety and immune response in a model with biological systems closely mirroring those of humans. The intranasal delivery resulted in measurable, TB-specific immune responses in both the bloodstream and the airways. These responses were characterized by durable, antigen-stimulated activity from both CD4 (helper) and CD8 (killer) T cells. Notably, these immune signatures persisted for at least six months, providing a promising indicator of the vaccine’s longevity. While the primate study focused on immune activation rather than protection against active infection, it represents a critical translational bridge toward eventual human clinical trials.

The Case for Immunotherapy in Infectious Disease

The Johns Hopkins research represents a departure from traditional "drug-only" paradigms. Historically, the medical community has relied on antibiotic monotherapy or combination therapy to eradicate TB. However, the increasing prevalence of antimicrobial resistance (AMR) has forced a reassessment of this strategy.

Dr. Karanika and her colleagues argue that incorporating immunotherapy—using the body’s own defense mechanisms to assist pharmaceutical treatments—is essential for addressing the "persister" problem. Because DNA vaccines are generally stable, cost-effective, and efficient to produce, this therapeutic platform could offer a scalable solution for regions with high TB burdens where long-term hospitalization and complex drug monitoring are not always feasible.

The implications for public health are profound. If validated in human trials, this therapeutic vaccine could potentially shorten the required duration of TB treatment. For a patient, a shorter regimen is not merely a convenience; it is a critical factor in ensuring adherence to the full course of therapy, thereby reducing the likelihood of developing drug-resistant strains.

Expert Perspectives and Future Outlook

The research team is comprised of a diverse group of experts, including specialists from the Johns Hopkins Center for Tuberculosis Research and the Bloomberg School of Public Health. The project has received substantial backing from federal institutions, including the National Institutes of Health, alongside support from specialized research foundations such as the Willowcraft Foundation and the Potts Memorial Foundation.

While the data are encouraging, the path to clinical application remains long. The team emphasizes that further preclinical testing is necessary to define optimal dosing, safety profiles, and long-term efficacy before the vaccine can be introduced into human clinical trial phases. The researchers have taken proactive steps in protecting the intellectual property associated with the vaccine, as several team members are listed as inventors on patent PCT/US2023/065584.

As the global health community grapples with the persistent shadow of tuberculosis, the work of the Johns Hopkins team provides a clear, evidence-based roadmap for potential progress. By focusing on the biological nuances of bacterial dormancy and leveraging the body’s mucosal immunity, this intranasal DNA vaccine offers a glimpse into a future where tuberculosis may be managed with greater precision and shorter, more effective treatment cycles.

Summary of Research Findings

• Target: The vaccine specifically disrupts the survival of drug-tolerant "persister" TB bacteria.
• Delivery: Intranasal administration targets the respiratory mucosa to generate localized, durable T-cell immunity.
• Efficacy: Mouse models showed faster bacterial clearance, reduced inflammation, and prevention of relapse.
• Compatibility: The vaccine enhances the effectiveness of current drug combinations, including those used for drug-resistant TB.
• Durability: Nonhuman primate studies confirmed that antigen-stimulated immune responses remained active for at least six months.

The global medical community is closely monitoring these developments. Given the ongoing rise of drug-resistant pathogens, the transition toward adjunctive immunotherapies—like the vaccine developed at Johns Hopkins—could define the next generation of infectious disease control. As the researchers move toward the next phases of development, the focus will remain on translating these strong preclinical signals into tangible patient benefits.